Fundraising FoxViking Global Investors — 2020 Investments
5 investments dated 2020 · listed companies and verified rows first · show all
4DMT is a late-stage biotechnology company that develops gene delivery systems and genetic therapeutics targeting specific tissue types for various diseases.
BiotechHealthtechEmeryville, US
David Kirn(Chief Executive Officer, President, and Co-Founder)inDavid Schaffer(Director)inTheresa Janke(Chief of Staff, Co-Founder)in
BoardSharon Tetlow(Director)Margi McLoughlin(Director)
Co-investorsAmzak HealthBerkeley CatalystBOLD LongevityCasdin CapitalChiesi VenturesPappas Capital+7 more
A biotechnology company developing new therapies for patients with high unmet medical needs.
Biotech
Co-investorsDolby Family VenturesLifeSci Venture PartnersSofinnova VenturesThe W FundViking GlobalCommodore Capital+6 more
Boost Biomes develops microbiome-based products using microbial community analysis to identify beneficial microbe interactions, with applications in agriculture.
Advanced ManufacturingAgTechBiotechFoodTechBrisbane, US
Jamie Bacher(Founder)inAdam Paul Arkin(Founder)inRobert McBridein
BoardErkki Aaltonen(Director)in
Co-investorsCompoundKickstart InnovationPlug and Play VenturesSaltagen VenturesUniversal Materials IncubatorY Combinator+10 more
Clinical-stage biotech developing cell therapy products for transplant and autoimmune conditions
BiotechLouisville, US
Suzanne Ildstad(Executive Officer, Director)Scott Requadt(Executive Officer, Director)Geoff Mackay(Director)Francois Nader(Director)
BoardSandip Agarwala(Director)inMark McDade(Director)in
Co-investorsAisling CapitalKeyhorse CapitalLongitude CapitalQiming Venture Partners USAViking GlobalBlackstone Life Sciences+3 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.